| Name: | Enalapril EP Impurity B |
| Catalogue No. | VL1360002 |
| CAS No. | 82717-96-2 |
| Molecular Formula | C15H21NO4 |
| Molecular Weight | 279.33 |
| Status | In-stock |
| IUPAC Name | ((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanine |
| Synonyms | Ramipril EP Impurity F / Quinapril EP Impurity B / Spirapril EP Impurity C / Moexipril Related Ccompound F / Enalaprilat EP Impurity F |
| Appearance | White Powder |
| Description | Enalapril EP Impurity B or Ramipril EP Impurity F / Quinapril EP Impurity B / Spirapril EP Impurity C / Moexipril Related Ccompound F / Enalaprilat EP Impurity F (CAS No.82717-96-2) or ((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanine. Enalapril is a prodrug that is hydrolyzed after absorption to form the active angiotensin-converting enzyme Enalaprilat. It is administered orally. It decreases blood pressure by lowering peripheral resistance without increasing heart rate. It is well tolerated an |
| References | "Davies, Richard O., et al. “Enalapril Worldwide Experience.” The American Journal of Medicine, vol. 77, no. 2, Aug. 1984, pp. 23–35, https://doi.org/10.1016/s0002-9343(84)80055-8. Todd, Peter A., and Karen L. Goa. “Enalapril.” Drugs, vol. 43, no. 3, Mar. 1992, pp. 346–81, https://doi.org/10.2165/00003495-199243030-00005. " |
